Coherus Oncology opened lower at $0.57, compared with its previous close of $0.58. In the last trading session, the stock traded between $0.51 and $0.58. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Coherus Oncology is now worth
$ 2.90
Resulting in a loss of
$ 97.10 (97.10%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.05 (-7.98%)
Day High
$0.58
Day Low
$0.51
Day Open
$0.57
Prev Close
$0.58
Volume
43,85,377
1W Return
-37.31%
1M Return
-48.21%
3M Return
-55.52%
6M Return
-72.51%
1Y Return
-60.30%
Market Cap ($ Mn)
83
PE Ratio
-
PB Ratio
3.58
PEG Ratio
-
ROE
-
ROCE
-121.74%
EPS (TTM)
$-0.25
1 Week
-37.31%
1 Month
-48.21%
3 Months
-55.52%
6 Months
-72.51%
9 Months
-73.73%
Guggenheim lowers Coherus Oncology price target to $8, keeps buy rating
Guggenheim lowers price target to $8 from $10. Analyst Paul Jeng maintains Buy rating on the stock. Valuation adjustment reflects current market assessment.
2 days agoCoherus Oncology to release tagmokitug interim data on October 28
Coherus Oncology will release interim clinical data for tagmokitug on October 28, 2026. The data covers the CCR8 antibody combined with toripalimab in multiple solid tumors. A management webcast will run from 4:30 pm to 6:00 pm ET on the disclosure date. Tagmokitug is currently in Phase 1b/2a studies for advanced solid tumors.
29 days agoCoherus Oncology retains Oppenheimer to sell legacy biosimilar assets
Coherus Oncology retained Oppenheimer & Co. to sell legacy biosimilar assets. Shareholders receive proceeds via CVRs distributed on October 7, 2026. Record date for CVR eligibility is September 30, 2026. Assets include patents, royalties, cell lines, and regulatory materials.
1mo agoCoherus Oncology to present at Baird, Wainwright, and Morgan Stanley conferences
Coherus Oncology will present at three major healthcare conferences in New York. Sessions scheduled for September 15 and 16, 2026 with Baird, Wainwright, and Morgan Stanley. Webcasts will be available live and as replays for 30 days. Investors can request one-on-one meetings with management via bank representatives.
2mo agoCoherus Oncology distributes biosimilar CVRs to shareholders
Coherus Oncology Inc (NASDAQ: CHRS) has announced a special dividend of contingent value rights (CVRs) to distribute value from its legacy biosimilar assets. The CVRs, distributed on October 7, 2026, entitle holders to pro rata shares of net cash proceeds from the sale or licensing of patents, IP, royalties, cell lines, and related materials. The company intends to immediately commence a sale process for these assets, retaining an investment bank as advisor. This move completes Coherus's transformation into a focused immuno-oncology company, allowing it to concentrate on its PD-1 inhibitor LOQTORZI and other pipeline candidates without the distraction of its former biosimilars business.
2mo agoCoherus Oncology Q2 Results: Revenue up 37% YoY, loss narrows
Coherus Oncology posted Q2 2026 net revenue of $14.3 million, up 37% YoY, driven by LOQTORZI sales growth. Net loss from continuing operations narrowed to $33.3 million from $44.9 million, supported by lower R&D and SG&A costs post-biosimilar exit. Pipeline candidates tagmokitug and casdozokitug advanced with data readouts expected in H2 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Coherus Oncology is now worth
$ 2.90
Resulting in a loss of
$ 97.10 (97.10%)
Note: Past profits do not guarantee future returns.
